[Corrections] Correction to Lancet Diabetes Endocrinol 2019; 7: 515–27

Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019: 7: 515–27—The appendix for this Article has been updated as of July 15, 2019.

Bekijk het originele bericht